Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer

Checkpoint immunotherapy is emerging as a new therapeutic approach for metastatic breast cancer. Monotherapy of immunoagents against PD1/PD-L1 or CTLA-4 has shown little efficacy in these patients. Recently, to determine the optimal use of immunotherapy, there has been a rapid expansion in the numbe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhi Bing, Zhang, Luyan, Bian, Jia, Jian, Jinbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133118/
https://www.ncbi.nlm.nih.gov/pubmed/32308409
http://dx.doi.org/10.2147/OTT.S240655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133118/
https://www.ncbi.nlm.nih.gov/pubmed/32308409
http://dx.doi.org/10.2147/OTT.S240655

Ejemplares similares